

1
2
3
4
5
6
7
8
9
10
11
12

Minutes
Meeting of the Toxicology Subcommittee
of the Scientific Advisory Committee
October 13, 2021
Department of Forensic Science, Central Laboratory, Classroom 1

13
14

Subcommittee Members Present

15
16

Randall Beaty, *Chair*

17
18

Marc LeBeau, Ph.D. (participated remotely pursuant to Virginia Code § 2.2-3708.2)

19
20

Richard P. Meyers

21
22

Staff Members Present

23
24

David A. Barron, Ph.D., Deputy Director

25
26

Nancy L. Batterson, Forensic Administrative Specialist III, *Secretary*

27
28

Katya N. Herndon, Chief Deputy Director

29
30

James W. Hutchings, Ph.D., Toxicology Program Manager

31
32

Linda C. Jackson, Director

33
34

Amy C. Jenkins, Department Counsel

35
36

Alka B. Lohmann, Director of Technical Services

37
38

Rebecca Wagner, Ph.D., Research Section Supervisor

39
40

Call to Order by Subcommittee Chair

41
42

Mr. Beaty called the meeting of the Toxicology Subcommittee (“Subcommittee”) to order at 8:01 a.m. He asked Katya Herndon, Chief Deputy Director, to address the remote participation of Dr. Marc LeBeau.

43
44
45
46
47

Ms. Herndon advised that Dr. LeBeau would be participating remotely pursuant to the Scientific Advisory Committee (SAC)’s Policy on Individual Participation in Scientific Advisory Committee Meetings by Electronic Means and in accordance with Virginia Code §2.2-3708.2. She noted that Dr. LeBeau would be participating by telephone from Fairfax, VA, due to a recent COVID exposure.

48
49

Adoption of Agenda

50
51
52
53
54

Mr. Beaty advised that the first order of business was the adoption of the draft agenda for the meeting and noted that the agenda was previously shared with the Subcommittee members. Mr. Meyers made a motion to adopt the agenda, which was seconded by Dr. LeBeau and passed by unanimous vote of the Subcommittee.

55

56

57

43 **Adoption of Draft Minutes from the July 13, 2020 Subcommittee Meeting**

44 Mr. Beaty noted that the draft minutes from the July 13, 2020 meeting of the Subcommittee were
45 previously shared and asked if there were any proposed changes. Being none, Mr. Meyers made a
46 motion that the minutes be approved, which was seconded by Dr. LeBeau and adopted by
47 unanimous vote.

48 **Discussion of Validation Plans**

49

50 In advance of the meeting, the members of the Subcommittee were provided validation plan
51 documentation for the following methods:

52

- 53 ● Cannabinoid Quantitation and Confirmation by Liquid-Liquid Extraction Using LCMSMS
- 54 ● Validation Plan for the Qualitative Analysis of Ephedrine using LCMSMS
- 55 ● Etizolam Quantitation and Confirmation by Liquid-Liquid Extraction Using LCMSMS

56

57 Rebecca Wagner, Ph.D., Research Section Supervisor, provided an overview of the validation plan
58 for each method.

59

60 After Dr. Wagner summarized the method validation plan for Cannabinoid Quantitation and
61 Confirmation by Liquid-Liquid Extraction Using LCMSMS, the Subcommittee members provided
62 comments and asked questions, which Dr. Wagner and Dr. Hutchings answered. Once the
63 discussion concluded, Mr. Beaty asked for a motion to close the review of the method validation
64 plan for the Cannabinoid Quantitation and Confirmation by Liquid-Liquid Extraction Using
65 LCMSMS. Mr. Meyers made a motion to close the review, which was seconded by Dr. LeBeau,
66 and passed by unanimous vote of the Subcommittee.

67

68 After Dr. Wagner summarized the method validation plan for the Qualitative Analysis of
69 Ephedrine using LCMSMS, the Subcommittee members provided comments and asked questions,
70 which Dr. Wagner answered. Mr. Beaty asked for a motion to close the review of the method
71 validation plan for the Qualitative Analysis of Ephedrine using LCMSMS. Mr. Meyers made a
72 motion to close the review, which was seconded by Dr. LeBeau and passed by unanimous vote of
73 the Subcommittee.

74 There were no comments or questions from the Subcommittee regarding the method validation
75 plan for Etizolam Quantitation and Confirmation by Liquid-Liquid Extraction Using LCMSMS.
76 Mr. Beaty asked for a motion to close the review of the method validation plan for the Etizolam
77 Quantitation and Confirmation by Liquid-Liquid Extraction Using LCMSMS. Mr. Meyers made
78 a motion to close the review, which was seconded by Dr. LeBeau and passed by unanimous vote
79 of the Subcommittee.

80 **Discussion of Validation Summaries**

81

82 In advance of the meeting, the members of the Subcommittee were provided copies of validation
83 summary documentation for the following methods:

84

- 85 ● Barbiturate Quantitation and Confirmation by LCMSMS

86 • Miscellaneous Basic Drugs Quantitation and Confirmation by LCMSMS

87 Dr. Wagner provided an overview of the method validation summary for Barbiturate Quantitation
88 and Confirmation by LCMSMS. There was discussion regarding the limit of detection specified
89 in the validation summary for two compounds, butabarbital and butalbital. Following the
90 discussion, Dr. LeBeau made a motion recommending that DFS update the validation summary to
91 raise the limit of detection for the two compounds discussed, which was seconded by Mr. Meyers
92 and passed by unanimous vote of the Subcommittee.

93 Mr. Beaty then asked for a motion to close the review of this validation summary. Mr. Meyers
94 made a motion to close the review, which was seconded by Dr. LeBeau and passed by unanimous
95 vote of the Subcommittee.

96 Dr. Wagner provided an overview of the method validation summary for Miscellaneous Basic
97 Drugs Quantitation and Confirmation by LCMSMS. The Subcommittee members and DFS staff
98 discussed the method validation summary. Based on the discussion, Dr. LeBeau made a motion to
99 recommend that DFS perform additional validation experiments to investigate a matched
100 deuterated internal standard for sertraline and the impact of ionization suppression and
101 enhancement with the minimum recommended number of blank matrices delineated in the ASB
102 036 validation standard. The motion was seconded by Mr. Meyers and passed by unanimous vote
103 of the Subcommittee.

104 Mr. Beaty subsequently asked for a motion to close the review of the validation summary for
105 Miscellaneous Basic Drugs Quantitation and Confirmation by LCMSMS. Dr. LeBeau made a
106 motion to close the review of the method validation summary with the recommendations that were
107 adopted, which was seconded by Mr. Meyers and passed by unanimous vote of the Subcommittee.
108 The Department indicated it would provide follow up at the next meeting in response to the
109 recommendations adopted.

110 **Discussion of Limit of Detection Experiments (Follow up from April 2021 Meeting)**

111 In advance of the meeting, the members of the Subcommittee were provided documentation for
112 the following limit of detection (LOD) experiments:

- 113 • Fentanyl Derivative Quantitation and Confirmation by LCMSMS
- 114 • GHB, GBL, and 1,4-Butanediol Quantitation and Confirmation by LCMSMS
- 115 • NSAID Quantitation and Confirmation by LCMSMS

116 Dr. Wagner provided an overview of each limit of detection experiment. The Subcommittee
117 members and DFS staff discussed the LOD experiment for GHB, GBL, and 1,4-Butanediol
118 Quantitation and Confirmation by LCMSMS. There were no questions or comments regarding the
119 other two LOD experiments.

120 Mr. Beaty then asked for a motion to close the review of the three LOD experiments. Mr. Meyers
121 made a motion to close the reviews, which was seconded by Dr. LeBeau and passed by unanimous
122 vote of the Subcommittee.

123

124 **Public Comment**

125 No member of the public was present to provide comment.

126 **Adjournment**

127 Mr. Beaty asked for a motion to adjourn the meeting. Mr. Meyers made a motion to adjourn the
128 meeting, which was seconded by Dr. LeBeau and passed by unanimous vote of the Subcommittee.
129 The meeting adjourned at 8:53 a.m.

130

131

132

133